+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2023-2033

  • PDF Icon

    Report

  • 284 Pages
  • October 2023
  • Region: Global
  • Visiongain
  • ID: 5806056
Description Jump to:
Overall world revenue for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 in terms of value will surpass US$15.0 billion in 2023. The author predicts strong revenue growth through to 2033. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise in Incidence of Retinal Disorders and Upsurge in Geriatric Population Driving Industry Growth

The growth of the market for Macular Degeneration (AMD) and Other Retinal Diseases is significantly driven by various important factors. A primary contributor is the increasing occurrence of retinal conditions, particularly macular degeneration. The prevalence of these ailments is on the upswing globally, attributed to factors such as the aging population, unhealthy lifestyles, and increased exposure to risk elements like smoking and extended screen usage. Macular degeneration, a primary cause of vision loss in older individuals, has gained notable attention in the field of ophthalmology, resulting in increased investments in research, development, and innovative treatment methods.

Furthermore, the rise in the elderly population significantly contributes to market growth. As people age, the likelihood of developing retinal conditions such as AMD rises. With a growing proportion of elderly individuals worldwide, there's a heightened demand for effective treatments to manage these conditions and preserve vision. This demographic shift accentuates the need for advanced therapeutics and comprehensive management strategies, driving the market for drugs and treatments targeting AMD and other retinal diseases.

In summary, the combination of a growing occurrence of retinal disorders and an expanding elderly population underscores the substantial demand for advancements in the Macular Degeneration (AMD) and Other Retinal Diseases Market. This highlights the importance of ongoing research, innovation, and accessible treatments to meet the evolving healthcare requirements of aging populations.

Lack of Awareness Regarding AMD Likely to Challenge Market Growth

The market for treating Macular Degeneration (AMD) and Other Retinal Diseases is significantly impacted by a major challenge - insufficient awareness regarding AMD. This predicament stems from a limited comprehension and knowledge within both the general populace and healthcare professionals about AMD, a progressive eye ailment that can result in vision impairment or loss. The issue centres around the fact that numerous individuals, particularly those in vulnerable demographics, lack awareness about the risk factors, symptoms, and potential consequences associated with AMD.

This deficiency in awareness creates notable obstacles for early diagnosis and timely intervention, as affected individuals may fail to identify the indicators of AMD until it reaches an advanced stage, diminishing the effectiveness of treatment options. Moreover, healthcare providers may face difficulty in detecting AMD during its initial phases due to the absence of routine screenings and inadequate public education about the condition.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the macular degeneration (AMD) and other retinal diseases drugs market evolving?
  • What is driving and restraining the macular degeneration (AMD) and other retinal diseases drugs market?
  • How will each macular degeneration (AMD) and other retinal diseases drugs market segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each macular degeneration (AMD) and other retinal diseases drugs market submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading macular degeneration (AMD) and other retinal diseases drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of macular degeneration (AMD) and other retinal diseases drugs projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the macular degeneration (AMD) and other retinal diseases drugs market?
  • Where is the macular degeneration (AMD) and other retinal diseases drugs market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market today, and over the next 10 years:

  • This 284-page report provides 115 tables, 151 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, this new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising drug development prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Disease Indication

  • AMD
  • Wet AMD
  • Dry AMD
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Others

Route of Administration

  • Parenteral
  • Topical

Brands

  • Lucentis
  • Eylea
  • Avastin
  • Beovu
  • Vabysmo
  • Ozurdex
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacy
  • E-commerce Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

MEA

  • GCC Countries
  • South Africa
  • Rest of MEA
The report also includes profiles and for some of the leading companies in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

  • AbbVie Inc.
  • Alimera Sciences
  • Apellis Pharmaceuticals
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Breye Therapeutics ApS
  • EyeBio
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • SpliceBio
  • Teva Pharmaceutical Industries Ltd.

How will the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 report help you?

In summary, the 280+ page report provides you with the following knowledge:
  • Revenue forecasts to 2033 for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 Market, with forecasts for disease indication, route of administration, distribution channel, and brand each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 24 key national markets - See forecasts for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Drug Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rise in Incidence of Retinal Disorders
3.2.1.2 Upsurge in Geriatric Population
3.2.1.3 Rising Healthcare Expenditure by Various Governments
3.2.2 Market Restraining Factors
3.2.2.1 Lack of Awareness Regarding AMD
3.2.2.2 Side Effects of Drugs
3.2.2.3 High Cost Associated with Macular Degeneration and Other Retinal Diseases
3.2.3 Market Opportunities
3.2.3.1 Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Disorders to Aid Market
3.2.3.2 Untapped Opportunities for the Dry AMD Treatment
3.2.3.3 Increasing Adoption of New Technologies for Treatment
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political
3.5.2 Economical
3.5.3 Social
3.5.4 Technological
4 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Disease Indication
4.1 Key Findings
4.2 Disease Indication Segment: Market Attractiveness Index
4.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
4.4 AMD
4.4.1 Market Size by Region, 2023-2033 (US$ Billion)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.4.3 AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market
4.5 Diabetic Macular Edema
4.5.1 Market Size by Region, 2023-2033 (US$ Billion)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Diabetic Retinopathy
4.6.1 Market Size by Region, 2023-2033 (US$ Billion)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Retinal Vein Occlusion
4.7.1 Market Size by Region, 2023-2033 (US$ Billion)
4.7.2 Market Share by Region, 2023 & 2033 (%)
4.8 Others
4.8.1 Market Size by Region, 2023-2033 (US$ Billion)
4.8.2 Market Share by Region, 2023 & 2033 (%)
5 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Route of Administration
5.1 Key Findings
5.2 Route of Administration Segment: Market Attractiveness Index
5.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of administration
5.4 Intravitreal Route
5.4.1 Market Size by Region, 2023-2033 (US$ Billion)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Intravenous Route
5.5.1 Market Size by Region, 2023-2033 (US$ Billion)
5.5.2 Market Share by Region, 2023 & 2033 (%)
6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Distribution Channel Segment: Market Attractiveness Index
6.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution Channel
6.4 Hospital Pharmacies
6.4.1 Market Size by Region, 2023-2033 (US$ Billion)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Retail Pharmacy
6.5.1 Market Size by Region, 2023-2033 (US$ Billion)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 E-Commerce Pharmacy
6.6.1 Market Size by Region, 2023-2033 (US$ Billion)
6.6.2 Market Share by Region, 2023 & 2033 (%)
7 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Brands
7.1 Key Findings
7.2 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Brands
8 Macular degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Region
8.1 Key Findings
8.3 Regional Market Size Estimation and Forecast
9 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
9.1 Key Findings
9.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
9.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
9.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
9.5 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
9.5.1 North America AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
9.6 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
9.7 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
9.8 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
9.9 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.1 Key Findings
10.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
10.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
10.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
10.5 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
10.5.1 Europe AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
10.6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
10.7 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
10.8 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.9 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.10 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.11 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.12 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.13 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.14 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.15 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.1 Key Findings
11.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
11.3 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
11.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
11.5 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
11.5.1 Asia-Pacific AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
11.6 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
11.7 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
11.8 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.9 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.10 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.11 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.12 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.13 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.14 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12.1 Key Findings
12.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
12.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
12.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
12.5 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
12.5.1 Latin America AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
12.6 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
12.7 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution Channel
12.8 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12.9 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12.10 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12.11 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
13 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
13.1 Key Findings
13.2 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
13.3 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
13.4 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
13.5 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
13.5.1 MEA AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
13.6 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
13.7 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
13.8 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
13.9 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
13.10 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
14 Company Profiles
14.1 Competitive Landscape, 2023
14.2 Strategic Outlook
14.3 Novartis AG
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2018-2022
14.3.3.2 Regional Market Shares, 2022
14.3.3.3 R&D Expense, 2018-2022
14.3.4 Product Offered
14.3.5 Strategic Outlook
14.4 Bayer AG
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2018-2022
14.4.3.2 Regional Market Shares, 2022
14.4.3.3 R&D Expense, 2018-2022
14.4.4 Products Offered
14.4.5 Strategic Outlook
14.5 Pfizer Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Revenue, 2018-2022
14.5.3.2 Regional Market Shares, 2022
14.5.3.3 R&D Expense, 2018-2022
14.5.4 Products Offered
14.5.5 Strategic Outlook
14.6 Bausch & Lomb Incorporated
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Revenue, 2018-2022
14.6.3.2 R&D Expense, 2018-2022
14.6.4 Products Offered
14.6.5 Strategic Outlook
14.7 Santen Pharmaceutical Co., Ltd.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Revenue, 2018-2022
14.7.3.2 R&D Expense, 2018-2022
14.7.4 Products Offered
14.7.5 Strategic Outlook
14.8 Johnson & Johnson Services, Inc.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Revenue, 2018-2022
14.8.3.2 Regional Market Shares, 2022
14.8.3.3 R&D Expense, 2018-2022
14.8.4 Products Offered
14.8.5 Strategic Outlook
14.9 Regeneron Pharmaceuticals Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Revenue, 2018-2022
14.9.3.2 R&D Expense, 2018-2022
14.9.4 Products Offered
14.9.5 Strategic Outlook
14.10 AbbVie Inc.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Revenue, 2018-2022
14.10.3.2 Regional Market Shares, 2022
14.10.3.3 R&D Expense, 2018-2022
14.10.4 Products Offered
14.10.5 Strategic Outlook
14.11 F. Hoffmann-La Roche Ltd.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Revenue, 2018-2022
14.11.3.2 Regional Market Shares, 2022
14.11.4 Products Offered
14.11.5 Strategic Outlook
14.12 Teva Pharmaceutical Industries Ltd.
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Revenue, 2018-2022
14.12.3.2 Regional Market Shares, 2022
14.12.3.3 R&D Expense, 2018-2022
14.12.4 Products Offered
14.12.5 Strategic Outlook
14.13 Apellis Pharmaceuticals
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Revenue, 2018-2022
14.13.3.2 R&D Expense, 2018-2022
14.13.4 Products Offered
14.13.5 Strategic Outlook
14.14 Alimera Sciences
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.3.1 Revenue, 2018-2022
14.14.3.2 R&D Expense, 2018-2022
14.14.4 Products Offered
14.14.5 Strategic Outlook
14.15 EyeBio
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Products Offered
14.15.4 Strategic Outlook
14.16 SpliceBio
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Products Offered
14.16.4 Strategic Outlook
14.17 Breye Therapeutics ApS
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Products Offered
14.17.4 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks
15.2 Recommendations for Market Players
List of Tables
Table 1 Macular degeneration (AMD) and other retinal diseases drug market Snapshot, 2023 & 2033 (US$ billion, CAGR %)
Table 2 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 7 AMD Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 8 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 9 Diabetic Macular Edema Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 10 Diabetic Retinopathy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 11 Retinal Vein Occlusion Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 12 Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 13 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 14 Intravitreal Route Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 15 Intravenous Route Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 16 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 17 Hospital Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 18 Retail Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 19 E-Commerce Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 20 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 21 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 22 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 23 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 24 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 25 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 26 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 27 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 28 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 29 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 30 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 31 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 32 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 33 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 34 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 35 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 36 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 37 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 38 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 39 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 40 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 41 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 42 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 43 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 44 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 45 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 46 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 47 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 48 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 49 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 50 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 51 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 52 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 53 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 54 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 55 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 56 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 57 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 58 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 59 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 60 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 61 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 62 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 63 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 64 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 65 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 66 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 67 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 68 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 69 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 70 Strategic Outlook
Table 71 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 72 Novartis AG: Products Offered
Table 73 Novartis AG: Strategic Outlook
Table 74 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Bayer AG: Products Offered
Table 76 Bayer AG: Strategic Outlook
Table 77 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 Pfizer Inc.: Products Offered
Table 79 Pfizer Inc.: Strategic Outlook
Table 80 Bausch & Lomb Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Bausch & Lomb Incorporated: Products Offered
Table 82 Bausch & Lomb Incorporated: Strategic Outlook
Table 83 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Santen Pharmaceutical Co., Ltd.: Products Offered
Table 85 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
Table 86 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Johnson & Johnson Services, Inc.: Products Offered
Table 88 Johnson & Johnson Services, Inc.: Strategic Outlook
Table 89 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Regeneron Pharmaceuticals Inc.: Products Offered
Table 91 Regeneron Pharmaceuticals Inc.: Strategic Outlook
Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AbbVie Inc.: Products Offered
Table 94 AbbVie Inc.: Strategic Outlook
Table 95 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 F. Hoffmann-La Roche Ltd.: Products Offered
Table 97 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 98 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Teva Pharmaceutical Industries Ltd.: Products Offered
Table 100 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 101 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Apellis Pharmaceuticals: Products Offered
Table 103 Apellis Pharmaceuticals: Strategic Outlook
Table 104 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Alimera Sciences: Products Offered
Table 106 Alimera Sciences: Strategic Outlook
Table 107 EyeBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 EyeBio: Products Offered
Table 109 EyeBio: Strategic Outlook
Table 110 SpliceBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 SpliceBio: Products Offered
Table 112 SpliceBio: Strategic Outlook
Table 113 Breye Therapeutics ApS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 Breye Therapeutics ApS: Products Offered
Table 115 Breye Therapeutics ApS: Strategic Outlook
List of Figures
Figure 1 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Segmentation
Figure 2 Macular degeneration (AMD) and other retinal diseases drug market by Disease Indication: Market Attractiveness Index
Figure 3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration: Market Attractiveness Index
Figure 4 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 5 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index by Region
Figure 6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Market Dynamics
Figure 7 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Porter’s Five Forces Analysis
Figure 12 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: PEST Analysis
Figure 13 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication: Market Attractiveness Index
Figure 14 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 15 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023, 2028, 2033 (%)
Figure 16 Prescription Drugs Market Forecast by Region, 2023 2033 (US$ Billion)
Figure 17 Prescription Drugs Market Share Forecast by Region, 2023 & 2033 (%)
Figure 18 Diabetic Macular Edema Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 19 Diabetic Macular Edema Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 Diabetic Retinopathy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 21 Diabetic Retinopathy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Retinal Vein Occlusion Segment Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 23 Retinal Vein Occlusion Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Others Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 25 Others Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration: Market Attractiveness Index
Figure 27 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 28 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of administration, 2023, 2028, 2033 (%)
Figure 29 Intravitreal Route Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 30 Intravitreal Route Market Share Forecast by Region, 2023 & 2033 (%)
Figure 31 Intravenous Route Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 32 Intravenous Route Market Share Forecast by Region, 2023 & 2033 (%)
Figure 33 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Phase: Market Attractiveness Index
Figure 34 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast By Distribution Channel, 2023-2033 (US$ Billion)
Figure 35 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023, 2028, 2033 (%)
Figure 36 Hospital Pharmacies Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 37 Hospital Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 38 Retail Pharmacy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 39 Retail Pharmacy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 40 E-Commerce Pharmacy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 41 E-Commerce Pharmacy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 42 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast By Brands, 2023-2033 (US$ Billion)
Figure 43 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Brands, 2023, 2028, 2033 (%)
Figure 44 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Region 2023 & 2033 (Revenue, CAGR%)
Figure 45 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 46 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%))
Figure 47 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 48 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by region, 2023, 2028 & 2033 (US$ Billion)
Figure 49 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 50 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 51 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 52 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 53 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 54 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 55 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 56 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 57 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 58 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 59 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 60 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 61 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 62 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 63 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 64 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 65 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 66 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 67 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 68 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 69 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 70 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 71 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 72 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 73 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 74 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 75 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 76 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 77 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 78 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 79 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 80 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 81 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 82 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 83 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 84 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 85 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 86 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 87 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 88 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 89 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 90 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 91 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 92 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 93 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 94 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 95 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 96 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 97 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 98 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 99 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 100 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 101 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 102 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 103 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 104 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 105 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 106 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 107 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 108 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 109 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 110 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 111 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 112 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 113 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 114 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 115 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 116 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 117 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 118 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 119 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 120 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 121 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Company Share Analysis, 2023
Figure 122 Novartis AG: Net Revenue, 2018-2022 (US$ million, AGR%)
Figure 123 Novartis AG: Regional Market Shares, 2022
Figure 124 Novartis AG: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 125 Bayer AG: Net Revenue, 2018-2022 (US$ million, AGR%)
Figure 126 Bayer AG: Regional Market Shares, 2022
Figure 127 Bayer AG: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 128 Pfizer Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 129 Pfizer Inc.: Regional Market Shares, 2022
Figure 130 Pfizer Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 131 Bausch & Lomb Incorporated: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 132 Bausch & Lomb Incorporated: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 133 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 134 Santen Pharmaceutical Co., Ltd.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 135 Johnson & Johnson Services, Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 136 Johnson & Johnson Services, Inc.: Regional Market Shares, 2022
Figure 137 Johnson & Johnson Services, Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 138 Regeneron Pharmaceuticals Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 139 Regeneron Pharmaceuticals Inc: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 140 AbbVie Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 141 AbbVie Inc.: Regional Market Shares, 2022
Figure 142 AbbVie Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 143 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 144 F. Hoffmann-La Roche Ltd.: Regional Market Shares, 2022
Figure 145 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 146 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
Figure 147 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 148 Apellis Pharmaceuticals: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 149 Apellis Pharmaceuticals: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 150 Alimera Sciences: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 151 Alimera Sciences: R&D Expense, 2018-2022 (US$ million, AGR%)

Companies Mentioned

  • AbbVie Inc.
  • Alimera Sciences
  • Apellis Pharmaceuticals
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Breye Therapeutics ApS
  • EyeBio
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • SpliceBio
  • Teva Pharmaceutical Industries Ltd.
  • Arena Pharmaceuticals
  • Astellas Pharma Inc.
  • Clearside Biomedical
  • Coopervision Company
  • Golgi Neurosciences S.r.l.
  • Horus Pharma
  • iSTAR Medical SA
  • Iveric bio, Inc.
  • Jeito Capital
  • Kedalion Therapeutics
  • Samsara BioCapital
  • SV Health Investors
  • UBE Corporation
  • Ysios Capital
  • American Academy of Ophthalmology (AAO)
  • American Glaucoma Society (AGS)
  • American Uveitis Society (AUS)
  • Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • British Ophthalmic Anaesthesia Society (BOAS)
  • Canadian Ophthalmological Society (COS)
  • European Society of Ophthalmology (SOE)
  • International Society for Ocular Oncology (ISOO)
  • Japanese Ophthalmological Society (JOS)
  • Latin American Society of Cataract and Refractive Surgery (LASCRS)
  • Ocular Microbiology and Immunology Group (OMIG)
  • Ophthalmic Anesthesia Society (OAS)
  • Ophthalmic Pharmaceutical Research Society (OPRS)
  • Optometric Glaucoma Society (OGS)

Related Topics

Related Reports

Macular Degeneration Treatment Global Market Report 2024 - Product Image

Macular Degeneration Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Dry Age-related Macular Degeneration (Dry-AMD) - Pipeline Insight, 2024 - Product Image

Dry Age-related Macular Degeneration (Dry-AMD) - Pipeline Insight, 2024

  • Clinical Trials
  • 240 Pages
  • Global
From
Macular Degeneration Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029 - Product Image

Macular Degeneration Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029

  • Report
  • 131 Pages
  • Global
From
Macular Degeneration Pipeline Analysis Report - Product Image

Macular Degeneration Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024 - Product Image

Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024

  • Clinical Trials
  • 240 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.